Skip to main content

Table 1 Data in whole cohort (n = 60) at the time of the most recent liver biopsy

From: Hepatic steatosis in patients with HIV-Hepatitis C Virus coinfection: is it associated with antiretroviral therapy and more advanced hepatic fibrosis?

Age at biopsy (yrs) 39.4 ± 8.2
Ethnicity  
White 24 (40%)
Other European 24 (40%)
Others 12 (20%)
Male 54 (90%)
Weight (kg) 72.3 ± 10.1
   > 75 kg 24 (40%)
Diabetes Mellitus 3 (5%)
Lipoatrophy 5 (8%)
Risk factors for HCV  
IDU 32 (53%)
Blood transfusion 3 (5%)
Homosexual 19 (32%)
Heterosexual 3 (5%)
Tattoos/fisting 3 (5%)
Unknown 1 (2%)
Alcohol Abuse 18 (30%)
CD4+ (/mm3) 450 (100–1200)
HIV VL (copies/ml) UD (UD-210,955)
Antiretroviral therapy  
None 17 (28%)
NRTI only 10 (17%)
HAART only 22 (37%)
Sequential therapy 11 (18%)
HCV VL (IU/ml)* 869,299 (2716–14,975,540)
HCV genotype 1* 30/42 (71%)
HCV disease duration (yrs) 16.4 ± 8.0
Liver Biopsy**  
Fibrosis stage 2.8 ± 1.7
Fibrosis progression rate/yr 0.21 ± 0.16
(FPR)*  
Cirrhosis 15 (25%)
Necroinflammatory grade 3.7 ± 1.7
Hepatic steatosis 35 (58%)
  1. *HCV viral load and genotyping unavailable in 16 and 18 patients respectively
  2. *FPR unavailable in 22 patients
  3. ** Data in median (range): fibrosis stage 2 (0–6), necroinflammatory grade 3 (1–9), fibrosis progression rate/yr 0.15 (0–0.67), steatosis grade 1 (0–3)
  4. UD: undetectable
  5. Ethnicity: In Other European the country of origin was as follows: Italy n = 8, Portugal n = 8, Spain n = 5, Germany n = 1, France n = 1 and Venezuela n = 1. Others included Brazil n = 3, Russia n = 3, Yugoslavia n = 3, India n = 1, Iran n = 1 and Libya n = 1